Kamada (KMDA) Buy Rating Maintained at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- First Financial to acquire Hickory Point Bank in $111.3M deal
Kamada (KMDA) Reports Holdings with EMA Over Proposed AATD Treatment
January 7, 2015 9:33 AM ESTKamada (NASDAQ: KMDA) provides a clinical/regulatory update.
Kamada has held encouraging pre-submission meetings with its European rapporteur and co-rapporteur with regard to the Companys Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for its inhaled alpha-1 antitrypsin (AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD). The co-rapporteurs advised that they would consider the entire study data once submitted, including post hoc analysis and will not reject the application simply because the primary endpoint of the study was not... More